Xenon Pharmaceuticals XENE Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's change in AP?
- Xenon Pharmaceuticals (XENE) reported change in AP of -$1.8M in Q1 2026.
- How has Xenon Pharmaceuticals's change in AP changed year-over-year?
- Xenon Pharmaceuticals's change in AP increased by 52.4% year-over-year, from -$3.78M to -$1.8M.
- What is the long-term trend for Xenon Pharmaceuticals's change in AP?
- Over 2 years (2021 to 2025), Xenon Pharmaceuticals's change in AP has grown at a 36.2% compound annual growth rate (CAGR), from $2.97M to $5.51M.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.